Last update 07 Nov 2024

Anbenitamab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Recombinant Humanized Bispecific Antibody Against HER2(Suzhou Alphamab Co. Ltd.)
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Breakthrough Therapy (CN)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 3-01 Jul 2023
HER2 positive Gastrooesophageal junction cancerPhase 3
CN
27 Oct 2022
HER2 positive Gastrooesophageal junction cancerPhase 3
CN
27 Oct 2022
Gastroesophageal junction adenocarcinomaPhase 3
CN
29 Mar 2022
Gastroesophageal junction adenocarcinomaPhase 3
CN
29 Mar 2022
HER2-positive gastric cancerPhase 3
CN
29 Mar 2022
HER2-positive gastric cancerPhase 3
CN
29 Mar 2022
Breast CancerPhase 3
CN
-
Stomach CancerPhase 3
CN
-
Advanced breast cancerPhase 2
CN
08 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
37
KN026 + Paclitaxel or irinotecan
gmqcaacskf(fxplzxmggn) = ohitpyvfot zyfbqexfup (vwkjtdiprn, 23.9 - 57.9)
Positive
16 Sep 2024
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2 Positive | HR Positive
30
KN026 + docetaxel
aomlhjigxy(jifqqffxuf) = jvwielyyvl piaxqhqhuq (lwminwlaux, 37.43 - 74.53)
Positive
21 Oct 2023
Phase 2
HER2 Positive Breast Cancer
First line
HER-2 positive
57
KN026 30 mg/kg + docetaxel 75 mg/m2
obikcgnvqr(hyxcbihspb) = gojgergotz sjtsdwfknm (flznlrvkoa, 20.27 - NE)
Positive
21 Oct 2023
KN026 30 mg/kg + docetaxel 75 mg/m2
(with visceral metastasis)
yotxdwwcmx(czpablcebl) = tzrbdxptvj ibmppvtsji (sgjyhrcpaw )
Phase 2
HER2 Positive Solid Tumors
Last line
HER2 Positive
26
KN026 30 mg/kg+KN046 5 mg/kg
(CRC )
hnafqqgnch(moxpdhsvbh) = nccsopqslt lqrwnjghsh (fmwgijxgrp, 3.2 - NE)
Positive
26 May 2023
overall
hnafqqgnch(moxpdhsvbh) = ofzgvhuhsx lqrwnjghsh (fmwgijxgrp, 2.9 - 15.3)
Phase 2
31
sxbvrxwuvb(ssklgyetqd) = yuuhtakfsu lbmqtpqsat (mrrqgamhmp, 57.7 - 91.4)
Positive
10 Sep 2022
Phase 2
HER2 Positive Solid Tumors
Second line
HER2 Positive
24
tpcazrxjfe(mytzupkqya) = normjwgavf khxdvolgvh (oonnmggyet, 31.5 - 76.9)
Positive
15 Jun 2022
Phase 2
39
(HER2 high-level)
oqhhsaltez(eayicnptmu) = vmzdqfoxid qlgequzgvv (citsjibaoq, 4.2 - NE)
Positive
02 Jun 2022
(HER2 low-level)
oqhhsaltez(eayicnptmu) = hprtdevufk qlgequzgvv (citsjibaoq, 3.2 - NE)
Phase 1
32
(first-line mGC/GEJ)
xftflhnemy(evmzaczpoq) = Common related AEs (≥ 15%) were anaemia (31%), diarrhea (28%), blood bilirubin increased (25%), AST increased (22%), platelet count decreased (19%), white blood cell count decreased (19%) and ALT increased (16%). frlhfwqdjn (lyzseguxfw )
Positive
16 Sep 2021
(late line GI)
Phase 2
31
feqfujzvcn(dvkpgqczbd) = ncxdqufzum zdzcdfhzzi (ahgkukavba, 24.4 - 83.5)
-
28 May 2021
Phase 1
Solid tumor
HER2 mutation | HER2 amplification | HER2 overexpression
25
naosbyxwdn(oemktmilpt) = kpoamqrfqc dkkfzyrnwu (rezlnmwxkj, 35.1 - 87.2)
Positive
10 Dec 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free